Table 2.
Current ongoing clinical trials evaluating the efficacy of promising compounds for treatment of pancreatic cancer.
| Compound | Treatment Regime | Subtype Specific Patient Stratification | Clinical Phase | NCT-Number |
|---|---|---|---|---|
| CPI-613 (Devimistat) | FOLFIRINOX | No | Phase 1/2 Recruiting |
NCT03699319 |
| Mitazalimab (CD40 agonist) | mFOLFIRINOX | No | Phase1b/2 Not yet recruiting |
NCT04888312 |
| LOAd703 (oncolytic adenovirus encoding TMZ-CD40L) | Gemcitabine+nab-paclitaxel+/-atezolizumab (anti PD-L1) | No | Phase 1/2a Recruiting |
NCT02705196 |
| CART-meso cells | / | No | Not applicable | NCT03638193 |
| / | No | Phase 1 | NCT03323944 | |
| Anti-CEA CAR-T cells | Systemic chemotherapy regimens | CEA-expressing PDAC with livermet | Phase 2b Recruiting |
NCT04037241 |
| / | CEA expressing tumors | Phase1/2 Recruiting |
NCT04348643 | |
| GVAX | Nivolumab, Ipilimumab, Cyclophosphamide, CRS-207 | No | Phase 2 Recruiting |
NCT03190265 |
| Epacadostat, Pembrolizumab, CRS-207, Cyclophosphamide | No | Phase 2 Recruiting |
NCT03006302 |